Tags : Terrosa

Daewon Pharmaceutical Launches its Terrosa (biosimilar, teriparatide) to Treat Osteoporosis

Vartika Singh May 26, 2020

Shots: Terrosa is a parathyroid hormone (PTH) gene recombination candidate originally developed by Richter-Helm Biotec to treat osteoporosis in men and postmenopausal women including those at high risk of fracture. Additionally, Terrosa has completed its P-I and P-III trials in EU and Japan has shown an increase in bone density in the spine, femur, and […]Read More

Insights+

Insights+ Key Biosimilars Events of August 2019

Vartika Singh September 6, 2019

Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of biosimilar space […]Read More

Biosimilars

Gedeon Richter Launches Terrosa (biosimilar, teriparatide) in Europe

Tuba Khan August 20, 2019

Shots: Richter has launched Terrosa, a biosimilar to Eli Lilly’s Forsteo approved for osteoporosis in postmenopausal women and in men at high risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture Richter launched Terrosa through its affiliates in Europe following the patent […]Read More

Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the US

Sanofi Collaborates with Sirion to Develop Gene Therapy Treatment with Improved AAV Capsids

UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development

Biocon Biologics and Viatris Receive CHMP’s Positive Opinion for Abevmy (biosimilar, bevacizumab)

Samsung Bioepis Initiates P-I Study of SB17 Proposed Biosimilar to Stelara (ustekinumab)

Takeda Reports NDA Submission to Import and Distribute Moderna’s mRNA-1273 in Japan

Regeneron’s Ab Cocktail (casirivimab + imdevimab) Receives the CHMP’s Positive Opinion to Treat COVID-19

Takeda Reports NDA Submission to Import and Distribute Moderna’s mRNA-1273 in Japan

Roche’s Actemra/RoActemra (tocilizumab) Receives the US FDA’s Approval as the First Biologic for Systemic Sclerosis-Associated Interstitial Lung Disease

Eli Lilly and Incyte Report Results of Olumiant (baricitinib) in P-III BRAVE-AA2 Study for Severe Alopecia Areata

Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for Type-2 Diabetes

Tags : Terrosa

Daewon Pharmaceutical Launches its Terrosa (biosimilar, teriparatide) to Treat Osteoporosis

Insights+ Key Biosimilars Events of August 2019

Gedeon Richter Launches Terrosa (biosimilar, teriparatide) in Europe

Latest Posts

PharmaShots Weekly Snapshots (Mar 01 – 05, 2021)

Eli Lilly and Incyte Report Results of Olumiant (baricitinib) in P-III BRAVE-AA2 Study for Severe Alopecia Areata

Takeda Reports NDA Submission to Import and Distribute Moderna’s mRNA-1273 in Japan

Roche’s Actemra/RoActemra (tocilizumab) Receives the US FDA’s Approval as the First Biologic for Systemic Sclerosis-Associated Interstitial Lung Disease

Tags : Terrosa

Latest Posts

Categories

Related Topics